{"product_id":"pkg-inhibitor-peptide-p1153","title":"PKG inhibitor peptide","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003ePKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM. The mapped target for this entry is cGMP-dependent protein kinases 1 and 2 (PRKG1 and PRKG2). In research settings, this mapped target is typically treated as a catalytic or regulatory node whose activity can alter substrate turnover, pathway flux, and stress responses over relatively short experimental time scales. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. In practical terms, the entry is well suited to mechanistic studies that require defined perturbation of pathway output over short experimental windows.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eIn inhibitor studies, researchers generally relate exposure to suppression of the mapped pathway, then compare phenotypic readouts with orthogonal markers of target engagement or pathway compensation. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because more than one mapped molecular node is represented in the enrichment, pathway readouts should be interpreted with awareness that the phenotype may integrate multiple signaling inputs.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003elink phenotypic changes to catalytic or substrate-based biomarkers rather than relying on a single endpoint\u003c\/li\u003e\n\u003cli\u003euse timed addition or washout designs when direct and downstream effects need to be separated\u003c\/li\u003e\n\u003cli\u003ebenchmark interpretation with orthogonal pathway controls or reference inhibitors where appropriate\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eExperimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.\u003c\/p\u003e\u003ch2\u003eFormat Considerations\u003c\/h2\u003e\u003cp\u003eFor routine mechanistic work, the unmodified catalog format provides a consistent starting point for concentration-response studies, benchmark experiments, and orthogonal validation. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"5 mg","offer_id":57636822286681,"sku":"P1153-5MG","price":274.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/p1153-pkg-inhibitor-peptide-chemical-structure.gif?v=1774212379","url":"https:\/\/absource.de\/products\/pkg-inhibitor-peptide-p1153","provider":"Absource Diagnostics","version":"1.0","type":"link"}